I joined D Young & Co in 2012. My expertise is in the life sciences and pharmaceuticals sectors, with a particular focus on RNA therapeutics, vaccines, infectious diseases, antibodies and gene editing. I enjoy making creative arguments, and being fully immersed in my client's patent strategy and portfolio in order to provide the highest level of service possible.
I advise a range of clients - including some of the world's largest pharmaceutical companies - on the drafting, prosecution, opposition and defence of their patents. In particular, I’ve successfully represented my clients in numerous contentious legal proceedings before the European Patent Office (EPO) opposition divisions and Boards of Appeal.
Before I joined D Young & Co, I completed a PhD in endothelial cell biology, focusing on pro-angiogenic signalling pathways. I’ve published many research papers in peer-reviewed journals and I’ve presented at bioscience and intellectual property conferences across the globe.
I have signed the IP Inclusive Senior Leaders' Pledge to demonstrate my personal commitment to improving diversity and inclusion (D&I) in our firm.
Ranked as a 'notable practitioner' by IPSTARS 2021.
- BA (Hons) in Natural Sciences (Biological), Queens' College, University of Cambridge.
- Foundation Scholarship for high achievement, University of Cambridge.
- PhD in Biochemistry and Molecular Biology, University of Leeds.
- Certificate in Intellectual Property Law, Queen Mary, University of London.
- Certificate in IP Litigation.
- Chartered Patent Attorney 2016.
- European Patent Attorney 2016.
- Chartered Institute of Patent Attorneys (CIPA).
- European Patent Institute (epi).
- Latham AM et al. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis. PLoS One 9: e110997 (2014).
- Fearnley GW et al. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol. Biol. Cell 25: 2509-21 (2014).
- Latham AM et al. Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells. Br. J. Pharmacol. 165: 245-59 (2012).